Loomis, Sayles & Company
PRVA icon

Loomis, Sayles & Company’s Privia Health PRVA Stock Holding History

Loomis, Sayles & Company’s Portfolio PRVA Stock Details PRVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1M Sell
1,014,786
-27,314
-3% -$633K 0.03% 207
2026
Q1 		$21.4M Sell
1,042,100
-26,921
-3% -$607K 0.03% 230
2025
Q4 		$25.3M Sell
1,069,021
-65,044
-6% -$1.58M 0.03% 195
2025
Q3 		$28.2M Sell
1,134,065
-43,032
-4% -$926K 0.03% 182
2025
Q2 		$27.1M Sell
1,177,097
-209,424
-15% -$4.85M 0.03% 189
2025
Q1 		$31.1M Sell
1,386,521
-31,713
-2% -$737K 0.05% 164
2024
Q4 		$27.7M Buy
1,418,234
+503,002
+55% +$9.97M 0.04% 211
2024
Q3 		$16.7M Sell
915,232
-1,572
-0.2% -$30K 0.02% 289
2024
Q2 		$15.9M Sell
916,804
-110,059
-11% -$1.95M 0.02% 284
2024
Q1 		$20.1M Buy
1,026,863
+190,540
+23% +$4.02M 0.03% 259
2023
Q4 		$19.3M Buy
836,323
+212,453
+34% +$4.75M 0.03% 260
2023
Q3 		$14.3M Buy
623,870
+7,577
+1% +$193K 0.02% 284
2023
Q2 		$16.1M Buy
+616,293
New +$16.3M 0.03% 276

Other funds holding PRVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RF
Rubicon Founders Nashville, Tennessee $196M AUM 53.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Loomis, Sayles & Company's PRVA Position: Q2 2026 in Review

Loomis, Sayles & Company reduced its Privia Health (PRVA) stake by 2.6% in Q2 2026, selling an estimated $633K and leaving 1,014,786 shares worth $26.1M. The position accounts for 0.03% of the portfolio, ranked #207.

Loomis, Sayles & Company first reported a position in PRVA in Q2 2023 and has held it in 13 quarters since. The position peaked at $31.1M in Q1 2025. 301 funds tracked by Wall St. Rank hold PRVA as of Q2 2026.

  • Loomis, Sayles & Company held 1,014,786 shares of Privia Health worth $26.1M as of Q2 2026.
  • Loomis, Sayles & Company sold 27,314 Privia Health shares in Q2 2026, an estimated $633K.
  • Privia Health made up 0.03% of Loomis, Sayles & Company's portfolio in Q2 2026, its #207 holding.
  • Loomis, Sayles & Company first reported a position in Privia Health in Q2 2023 and has held it in 13 quarters since.
  • Loomis, Sayles & Company's Privia Health position peaked at $31.1M in Q1 2025.
  • 301 funds tracked by Wall St. Rank held Privia Health as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.